Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration.
There are many reports of intravenous erythromycin causing QT prolongation and torsades de pointes, but this complication is seldom ascribed to orally administered erythromycin, which is by far the most commonly prescribed route. This report describes a case of torsades de pointes associated with oral erythromycin as a result of a previously undescribed interaction with carbimazole, an antithyroid drug that is metabolized to the active drug methimazole, and the potential pharmacokinetic and pharmacodynamic mechanisms are highlighted.
Koh
T W
TW
Department of Cardiology, St Bartholomew's Hospital, London, England. t.koh@which.net
D000284:Administration, Oral; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D013956:Antithyroid Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002231:Carbimazole / Q000008:administration & dosage / Q000009:adverse effects*; D004347:Drug Interactions; D004917:Erythromycin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008713:Methimazole / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors; D016171:Torsades de Pointes / Q000139:chemically induced*
D000900:Anti-Bacterial Agents; D013956:Antithyroid Agents; D008713:Methimazole; D004917:Erythromycin; D002231:Carbimazole